Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease

Sophie Laurent*, Mohammad Reza Ejtehadi, Meisam Rezaei, Patrick G. Kehoe, Morteza Mahmoudi

*Corresponding author for this work

Research output: Contribution to journalReview article (Academic Journal)peer-review

42 Citations (Scopus)

Abstract

During the last decade, reports show that the incidence and prevalence of Alzheimer's disease (AD) and other dementias have significantly increased. AD poses an enormous escalating threat to health services and resources. Early diagnosis of AD is recognized as one of the major challenges and primary aims in scientific communities. With the arrival of nanoscience and nanotechnology to medicine, hopes for early diagnosis and treatment of AD have considerably increased. To this end, nanobioresearchers are focused on three major areas consisting of early detection and recognition, biological markers and diagnosis, and pharmacotherapy. Several efforts are in progress for the discovery of new nanodrugs with a sufficient effort on the fast therapy of AD. In this review, a comprehensive overview of the conventional theories together with new conflicts and challenges on the major causes of AD is provided. In addition, the opportunities and challenges of nanoscience and nanotechnology as theranostic agents for AD are discussed in detail.
Translated title of the contributionInterdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease
Original languageEnglish
Pages (from-to)5008-5033
Number of pages26
JournalRSC Advances
Volume2
Issue number12
DOIs
Publication statusPublished - Mar 2012

Bibliographical note

Publisher: RSC Publishing

Keywords

  • LONG-TERM POTENTIATION
  • NEUROTROPHIC FACTOR
  • INCREASED PLASMA-LEVELS
  • UBIQUITIN-PROTEASOME SYSTEM
  • CEREBROSPINAL-FLUID
  • OXIDATIVE STRESS
  • AMYLOID-BETA-PEPTIDE
  • BLOOD-BRAIN-BARRIER
  • A-BETA
  • METHYL-D-ASPARTATE

Fingerprint Dive into the research topics of 'Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this